Panaxydol是从人参根中提取的一种C17-多炔醇类化合物，具有细胞毒性和抗微生物活性。
Cas No.:72800-72-7
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
Panaxydol, a C17-polyacetylene from Panax ginseng roots, exhibits cytotoxic and antimicrobial activities [1]. Panaxydol increased albumin secretion and alkaline phosphatase activity, and correspondingly decreased alpha-fetoprotein (AFP) secretion, as well as decreased the expression of Id1 regulator and increased the protein levels of p21 and p-ERK1/2 in liver carcinoma cell lines[2]. Panaxydol has been widely used to induce cancer cell death and promote Caspase-3 activation and PKCδ cleavage[3].
In vitro, Panaxydol treatment for 48 hours significantly inhibited the proliferation of rat C6 glioma cells, with an IC50 value of 39.5µM[4]. 10µM of Panaxydol incubation for 24 hours protected Schwann cells from hypoxia-induced cell death and increased the mRNA levels of neurotrophic factors NGF and BDNF[5]. Treatment with 50μg/ml Panaxydol for 2 hours significantly induced apoptosis in MCF-7 and Jurkat cells, promoting the release of mitochondrial cytochrome c and resulting in the loss of mitochondrial membrane potential[6].
In vivo, Panaxydol treatment via oral administration at a dose of 20mg/kg/day for 20 days significantly alleviated the kidney damage induced by aristolochic acid in rats, improved renal function, and promoted the expression levels of Nrf2, NQO1 and HO-1[7]. Continuous intraperitoneal injection of 20mg/kg dose of Panaxydol for three consecutive days significantly inhibited lipopolysaccharide (LPS)-induced acute lung injury (ALI) and ferroptosis in mice[8].
References:
[1] Knispel N, Ostrozhenkova E, Schramek N, et al. Biosynthesis of panaxynol and panaxydol in Panax ginseng[J]. Molecules, 2013, 18(7): 7686-7698.
[2] Wang Z J, Song L, Guo L C, et al. Induction of differentiation by panaxydol in human hepatocarcinoma SMMC-7721 cells via cAMP and MAP kinase dependent mechanism[J]. Yakugaku Zasshi, 2011, 131(6): 993-1000.
[3] Yan Z, Yang R, Jiang Y, et al. Induction of apoptosis in human promyelocytic leukemia HL60 cells by panaxynol and panaxydol[J]. Molecules, 2011, 16(7): 5561-5573.
[4] Hai J, Lin Q, Lu Y, et al. Growth inhibition and induction of differentiation by panaxydol in rat C6 glioma cells[J]. Neurological research, 2008, 30(1): 99-105.
[5] Zhu H, Wang W J, Ding W L, et al. Effect of panaxydol on hypoxia-induced cell death and expression and secretion of neurotrophic factors (NTFs) in hypoxic primary cultured Schwann cells[J]. Chemico-biological interactions, 2008, 174(1): 44-50.
[6] Kim J Y, Yu S J, Oh H J, et al. Panaxydol induces apoptosis through an increased intracellular calcium level, activation of JNK and p38 MAPK and NADPH oxidase-dependent generation of reactive oxygen species[J]. Apoptosis, 2011, 16(4): 347-358.
[7] Guo Y, Hu M, Ma J, et al. Protective effect of panaxydol against repeated administration of aristolochic acid on renal function and lipid peroxidation products via activating Keap1‐Nrf2/ARE pathway in rat kidney[J]. Journal of Biochemical and Molecular Toxicology, 2021, 35(1): e22619.
[8] Li J, Lu K, Sun F, et al. Panaxydol attenuates ferroptosis against LPS-induced acute lung injury in mice by Keap1-Nrf2/HO-1 pathway[J]. Journal of Translational Medicine, 2021, 19(1): 96.
Panaxydol是从人参根中提取的一种C17-多炔醇类化合物，具有细胞毒性和抗微生物活性[1]。Panaxydol能够增加白蛋白分泌和碱性磷酸酶活性，相应地降低甲胎蛋白（AFP）分泌，同时降低肝癌细胞系中Id1调节因子的表达，提高p21和p-ERK1/2的蛋白水平[2]。Panaxydol已被广泛用于诱导癌细胞死亡，并促进Caspase-3激活和PKCδ裂解[3]。
在体外，Panaxydol处理48小时显著抑制了大鼠C6胶质瘤细胞的增殖，IC50值为39.5µM[4]。使用10µM的Panaxydol孵育24小时，保护了雪旺细胞免受缺氧诱导的细胞死亡，并增加了神经营养因子NGF和BDNF的mRNA水平[5]。使用50µg/ml的Panaxydol处理2小时，显著诱导了MCF-7和Jurkat细胞凋亡，促进了线粒体细胞色素c的释放，并导致线粒体膜电位丧失 [6]。
在体内，每日口服20mg/kg剂量的Panaxydol，连续20天，显著减轻了马兜铃酸诱导的大鼠肾损伤，改善了肾功能，并促进了Nrf2、NQO1和HO-1的表达水平[7]。连续三天腹腔注射20mg/kg剂量的Panaxydol，显著抑制了脂多糖（LPS）诱导的小鼠急性肺损伤（ALI）和铁死亡[8]。
| Cell experiment [1]: | |
Cell lines | C9 cells |
Preparation Method | C9 cells were cultured in DMEM medium containing 10% fetal bovine serum (FBS), 100U/ml penicillin and 100mg/ml streptomycin at 37℃ in the presence of 5% CO2. Cells were plated onto a 96-well plate at a density of 1×104 cells/ml for 24h, and were treated with different concentrations of Panaxydol (0, 20, 40, 60, and 80µM). After 48 hours, cell viability was analyzed. |
Reaction Conditions | 0, 20, 40, 60, and 80µM; 48h |
Applications | Panaxydol treatment significantly reduced the cell viability of C9 cells in a dose-dependent manner. |
| Animal experiment [2]: | |
Animal models | Wistar male rats |
Preparation Method | Wistar male rats, weighing 110 to 130g, were housed in temperature (23±2°C) and light-controlled (12:12-hour light-dark cycle) animal care facility. The rats were divided into three groups: the first group was the control group, the second group was the aristolochic acid-induced group (5mg/kg/day; intraperitoneal injection for 10 consecutive days), and the third group was the aristolochic acid+Panaxydol group (20mg/kg/day; oral administration for 20 consecutive days). After the experiment, the rats were sacrificed and the kidney tissues were collected for histological analysis. |
Dosage form | 20mg/kg/day for 20 days; p.o. |
Applications | Panaxydol treatment ameliorated the kidney damage induced by aristolochic acid in rats. |
References: | |
| Cas No. | 72800-72-7 | SDF | |
| 别名 | 人参环氧炔醇 | ||
| Canonical SMILES | CCCCCCC[C@@H]1O[C@@H]1CC#CC#C[C@@H](C=C)O | ||
| 分子式 | C17H24O2 | 分子量 | 260.37 |
| 溶解度 | 5mg/mL in DMSO | 储存条件 | Store at -20°C,protect from light |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 3.8407 mL | 19.2034 mL | 38.4069 mL |
| 5 mM | 768.1 μL | 3.8407 mL | 7.6814 mL |
| 10 mM | 384.1 μL | 1.9203 mL | 3.8407 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >70.00% Appearance: A solution in DMSO
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet